Treatment of lymphatic malformations of head and neck with OK-432 sclerotherapy induce systemic inflammatory response
- 187 Downloads
Systemic immune responses after OK-432 (Picibanil) sclerotherapy in patients with head and neck lymphatic malformations (LM) were examined to achieve a better understanding of the mechanism of OK-432 sclerotherapy and to evaluate the long-term treatment outcome. Serum samples from 17 consecutive patients with head and neck LMs were collected during a total of 26 OK-432 treatment episodes. Serum C-reactive protein (CRP), interleukins (IL) 1β, 6, 8, 10, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, RANTES, immune protein (IP)-10 and macrophage chemoattractant protein (MCP)-1 as well as blood leukocyte counts were determined. Clinical outcome of the treatment was evaluated at the last visit and from patient files. Elevated serum levels of IP-10 (means at baseline 702 ng/L, after 1 day 1180 ng/L, after 4 weeks 691 ng/L) were seen on day one after OK-432 sclerotherapy (p < 0.05). C-reactive protein and leukocyte counts 1 day after treatment differed statistically significantly (p < 0.05) from the baseline. No significant differences with other cytokines investigated were observed. Patients with macrocystic LM responded better than patients with microcystic LM (p = 0.01). The elevated levels of IP-10, C-reactive protein and leukocyte levels indicate that OK-432 sclerotherapy induces systemic immune responses in patients with LM. The mechanisms of OK-432 sclerotherapy are still not precisely understood, but the IP-10 elevation may reflect local antiangiogenetic properties of immunoactivation induced by OK-432.
KeywordsOK-432 IP-10 Systemic inflammatory response Lymphatic malformation
We thank Kimmo Lappalainen, MD, for his kind help in processing the MRI scans.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
- 2.Marler JJ, Mulliken JB (2001) Vascular anomalies: classification, diagnosis, and natural history. Facial Plast Surg Clin North Am 4:495–504Google Scholar
- 3.Banieghbal B, Davies MR (2003) Guidelines for the successful treatment of lymphangioma with OK-432. Eur J Pediatr Surg 2:103–107Google Scholar
- 4.Giguere CM, Bauman NM, Sato Y, Burke DK, Greinwald JH, Pransky S, Kelley P, Georgeson K, Smith RJ (2002) Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial. Arch Otolaryngol Head Neck Surg 10:1137–1144Google Scholar
- 5.Orvidas LJ, Kasperbauer JL (2000) Pediatric lymphangiomas of the head and neck. Ann Otol Rhinol Laryngol 4:411–421Google Scholar
- 7.Rautio R, Keski-Nisula L, Laranne J, Laasonen E (2003) Treatment of lymphangiomas with OK-432 (Picibanil). Cardiovasc Intervent Radiol 1:31–36Google Scholar
- 8.Smith MC, Zimmerman MB, Burke DK, Bauman NM, Sato Y, Smith RJ, OK-432 Collaborative Study Group (2009) Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope 1:107–115Google Scholar
- 10.Ogita S, Tsuto T, Tokiwa K, Takahashi T (1987) Treatment of cystic hygroma in children with special reference to OK-432 therapy. Z Kinderchir 5:279–281Google Scholar
- 14.Abbas AK, Lichtman AH (2005) Cytokines. In: Anonymous cellular and molecular immunology, 5th edn. Elsevier, Saunders, p 243Google Scholar
- 15.Miettinen M, Vuopio-Varkila J, Varkila K (1996) Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 12:5403–5405Google Scholar
- 19.Smith MC, Zimmerman MB, Burke DK, Bauman NM, Sato Y, Smith RJ, the OK-432 Collaborative Study Group*OK-432 Collaborative Study Group (2008) Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope 1:107–115Google Scholar